guanabenz | 60329-05-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: guanabenz
• 英文别名: (Z)-guanabenz；2-[(Z)-(2,6-dichlorophenyl)methylideneamino]guanidine
• CAS: 60329-05-7
• 化学式: C₈H₈Cl₂N₄
• 分子量: 231.084
• InChiKey: WDZVGELJXXEGPV-PQMHYQBVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  76.8
• 氢给体数：
  2
• 氢受体数：
  2

ADMET

毒理性

• 在妊娠和哺乳期间的影响

◉ 母乳喂养期间使用总结：由于缺乏关于在哺乳期间使用胍那苄的信息，可能更倾向于使用其他药物，特别是在哺乳新生儿或早产儿时。 ◉ 对哺乳婴儿的影响：截至修订日期，没有找到相关的已发布信息。 ◉ 对泌乳和母乳的影响：截至修订日期，没有找到相关的已发布信息。

◉ Summary of Use during Lactation:Because no information is available on the use of guanabenz during breastfeeding, other agents may be preferred, especially while nursing a newborn or preterm infant. ◉ Effects in Breastfed Infants:Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk:Relevant published information was not found as of the revision date.

来源:Drugs and Lactation Database (LactMed)

反应信息

• 作为产物：
  描述：

  Guanabenz 以20%的产率得到
  参考文献：
  名称：

  TSUJIKAWA TERUAKI; MIZUTA EIJI; HAYASHI MASANORI, YAKUGAKU DZASSI, YAKUGAKU ZASSNI, J. PHARM. SOS. JAR. , 1976, 96+

  摘要：

  DOI：

文献信息

• Metabolic and cardiovascular benefits and risks of 4-hydroxy guanabenz hydrochloride: α2-adrenoceptor and trace amine-associated receptor 1 ligand
  作者：Magdalena Kotańska、Monika Marcinkowska、Kamil J. Kuder、Maria Walczak、Marek Bednarski、Agata Siwek、Marcin Kołaczkowski

  DOI：10.1007/s43440-023-00518-9

  日期：2023.10

  additional beneficial effect on selected metabolic parameters, including glucose levels. The purpose of this present research was to determine the activity of guanabenz's metabolite—4-hydroxy guanabenz hydrochloride (4-OH-Guanabenz). Methods We performed in silico analyses, involving molecular docking to targets of specific interest as well as other potential biological targets. In vitro investigations were

  背景 α 2 -肾上腺素受体配体已被研究作为治疗肥胖症的潜在治疗剂。我们之前的研究表明，胍那苯可以减轻肥胖大鼠的体重，大概是通过其厌食作用。这表明对选定的代谢参数（包括葡萄糖水平）具有额外的有益作用。本研究的目的是确定胍那苯的代谢物——4-羟基胍那苯盐酸盐（4-OH-Guanabenz）的活性。 方法 我们进行了计算机分析，涉及与特定感兴趣的目标以及其他潜在生物目标的分子对接。进行体外研究以评估 4-OH-Guanabenz 与 α-肾上腺素受体结合的选择性特征，以及涉及 α 2 -肾上腺素受体和痕量胺相关受体 1 (TAAR 1 ) 的内在活性研究。此外，使用饮食诱导的肥胖模型评估了 4-OH-Guanabenz 对大鼠体重和选定代谢参数的影响。还检查了基本安全性和药代动力学参数。 结果 4-OH-guanabenz 是 α 2A -肾上腺素受体的部分激动剂。计算得出的 EC 50值为 316
• Method for enhancing folding and transport of misfolded glucocerebrosidase
  申请人：The Hospital for Sick Children

  公开号：US10028922B2

  公开（公告）日：2018-07-24

  Therapeutic compositions and methods for treatment of late-onset Gaucher disease are described herein. The compositions comprise compounds having activity as pharmacological chaperones for mutant forms of the beta-glucocerebrosidase. Methods of treatment involve providing therapeutically effective amounts of such compositions to subjects in need thereof.

  本文描述了治疗晚发型戈谢病的治疗组合物和方法。这些组合物包括对突变形式的β-葡糖脑苷脂具有药理伴侣活性的化合物。治疗方法包括向有需要的受试者提供治疗有效量的此类组合物。
• Method of treating gaucher disease
  申请人：Mahuran Don J.

  公开号：US20090075960A1

  公开（公告）日：2009-03-19

  Therapeutic compositions and methods for treatment of late-onset Gaucher disease are described herein. The compositions comprise compounds having activity as pharmacological chaperones for mutant forms of the beta-glucocerebrosidase. Methods of treatment involve providing therapeutically effective amounts of such compositions to subjects in need thereof.
• METHOD OF TREATING GAUCHER DISEASE
  申请人：Mahuran Don J

  公开号：US20120021487A1

  公开（公告）日：2012-01-26

  Therapeutic compositions and methods for treatment of late-onset Gaucher disease are described herein. The compositions comprise compounds having activity as pharmacological chaperones for mutant forms of the beta-glucocerebrosidase. Methods of treatment involve providing therapeutically effective amounts of such compositions to subjects in need thereof.
• METHOD OF TREATING LYSOSOMAL STORAGE DISORDERS
  申请人：The Hospital for Sick Children

  公开号：US20140235713A1

  公开（公告）日：2014-08-21

  Therapeutic compositions and methods for treatment of late-onset Gaucher disease are described herein. The compositions comprise compounds having activity as pharmacological chaperones for mutant forms of the beta-glucocerebrosidase. Methods of treatment involve providing therapeutically effective amounts of such compositions to subjects in need thereof.